Xvivo Perfusion AB (STU:3XV)
€ 38.3 0.6 (1.59%) Market Cap: 1.23 Bil Enterprise Value: 1.19 Bil PE Ratio: 132.53 PB Ratio: 6.92 GF Score: 82/100

Q1 2019 Xvivo Perfusion AB Earnings Call Transcript

Apr 24, 2019 / 12:00PM GMT
Operator

Ladies and gentlemen, welcome to XVIVO Perfusion Q1 Report 2019. Today, I'm pleased to present CEO, Magnus Nilsson; and CFO, Christoffer Rosenblad.

(Operator Instructions)

Please go ahead with your meeting.

Magnus Nilsson;publ;CEO;MD
Xvivo Perfusion AB

()-&

Thank you very much, and welcome to the XVIVO Perfusion Q1 report. I'm Magnus Nilsson, and again, I have Christoffer Rosenblad on my side. You have to excuse me, I caught a cold on my way here the other day from the United States. So I hope that you can hear my voice good.

Let's go to Slide #2, highlights from '19 Q1. Reimbursement process for EVLP approved in France. We see very encouraging results from the first 6 patients in the lung study with the heart preservation device. It was presented at the yearly -- the annual heart and lung transplant congress with great interest. We also have presented this device for thought-leading heart transplant surgeons worldwide, and they've shown a great interest in starting clinical trials

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot